Sun Pharmaceutical Industries
NIFTY 50 weight · 1.80%
Reasoning Summary
AI-synthesized from the structured driver list. Never invents events.
Sun Pharmaceutical Industries shows a balanced bias with limited conviction. The dominant driver is USD/INR breaches 84.50, RBI intervenes with ~$2bn in spot market, categorized as currency. Bull-case items (2) and bear-case items (3) are both active — treat this as a net read, not a unanimous view. This is a decision-support read, not a price target.
- ▲Pharmaceuticals exposure — this event category is typically positive for SUNPHARMA (USD-denominated specialty business).
- ▲Pharmaceuticals is in the affected-sector set for this event.
- ▼Pharmaceuticals exposure — this event category is typically negative for SUNPHARMA.
- ▼Pharmaceuticals exposure — this event category is typically negative for SUNPHARMA (US FDA observations overhang).
- ▼Directly referenced in "FDA issues Form 483 to Sun Pharma Halol facility". Severity: high; freshness: 259h old.
Decision support, not investment advice. This platform provides AI-assisted market interpretation for research and monitoring. It does not constitute investment advice, portfolio management, or a recommendation to buy or sell securities.
Signal History
Trailing raw score (black) against confidence (amber). Dashed lines show current direction thresholds.
Sector Sensitivity
Exposure profile — how this stock typically reacts to each event category.
- Regulationnegative70
US FDA observations overhang
- Currencypositive55
USD-denominated specialty business
- Tariffnegative35
Top Event Drivers
Factual events with non-trivial contribution to this stock's signal, ordered by weight.
- 01▲ Currencyweight +2.74
USD/INR breaches 84.50, RBI intervenes with ~$2bn in spot market
Pharmaceuticals exposure — this event category is typically positive for SUNPHARMA (USD-denominated specialty business).
- 02▼ Tariffweight -2.16
US announces 15% tariff on Indian steel and aluminium imports
Pharmaceuticals exposure — this event category is typically negative for SUNPHARMA.
- 03▼ Regulationweight -0.88
SEBI tightens disclosure norms for related-party transactions
Pharmaceuticals exposure — this event category is typically negative for SUNPHARMA (US FDA observations overhang).
- 04▼ Regulationweight -0.87
FDA issues Form 483 to Sun Pharma Halol facility
Directly referenced in "FDA issues Form 483 to Sun Pharma Halol facility". Severity: high; freshness: 259h old.
- 05▲ Supply Chainweight +0.24
China announces rare-earth export quotas, impacts global supply chains
Pharmaceuticals is in the affected-sector set for this event.
Recent Event Stream
All ingested events from the last week — the raw evidence base.
- Geopolitics2 days ago
NATO-Russia tensions escalate after Baltic incident
- Commodity2 days ago
Gold surges past $2,450/oz on central bank buying, geopolitical hedging
- Commodity2 days ago
Brent crude surges to $94 on Middle East tensions, Houthi strikes
- Currency2 days ago
USD/INR breaches 84.50, RBI intervenes with ~$2bn in spot market
- Central Bank2 days ago
RBI holds repo rate steady at 6.25%, signals data-dependent stance
Reserve Bank of India - Tariff3 days ago
US announces 15% tariff on Indian steel and aluminium imports
- Guidance3 days ago
Infosys raises FY27 revenue guidance to 7-9% on AI deal wins
- Government Policy4 days ago
Union Cabinet approves PLI 2.0 for semiconductors, ₹76,000 cr outlay
- Climate4 days ago
Monsoon forecast: IMD predicts 103% of long-period average
- Earnings4 days ago
HDFC Bank Q4 NIM compresses to 3.4%, asset quality stable
- Climate5 days ago
Unseasonal rainfall damages kharif sowing across Maharashtra, Karnataka
- Supply Chain7 days ago
China announces rare-earth export quotas, impacts global supply chains
- Inflation7 days ago
CPI inflation prints 5.8% for March, above RBI tolerance band
- Regulation8 days ago
SEBI tightens disclosure norms for related-party transactions